Cynomolgus studies with lead TRACTrs have demonstrated safety proof-of-concept to support IND-enabling development activities. Janux-led TRACTr development candidate selection is ongoing with multiple programs entering IND-enabling studies in 2021 to provide a broad portfolio of tumor-specific immune-activating therapeutics. In addition, Janux is developing a costimulatory bispecific that has demonstrated activity both as a single-agent and in combination with TRACTrs.
|Lead Discovery||Lead Optimization||IND Enabling||Phase 1|
|Costim bispecific||Lead Optimization|